BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22825324)

  • 41. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
    Maurer M; Altrichter S; Bieber T; Biedermann T; Bräutigam M; Seyfried S; Brehler R; Grabbe J; Hunzelmann N; Jakob T; Jung A; Kleine-Tebbe J; Mempel M; Meurer M; Reich K; Ruëff F; Schäkel K; Sengupta K; Sieder C; Simon JC; Wedi B; Zuberbier T; Mahler V; Staubach P
    J Allergy Clin Immunol; 2011 Jul; 128(1):202-209.e5. PubMed ID: 21636116
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study.
    Penn R; Mikula S
    Am J Rhinol; 2007; 21(4):428-32. PubMed ID: 17882911
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.
    Djukanović R; Wilson SJ; Kraft M; Jarjour NN; Steel M; Chung KF; Bao W; Fowler-Taylor A; Matthews J; Busse WW; Holgate ST; Fahy JV
    Am J Respir Crit Care Med; 2004 Sep; 170(6):583-93. PubMed ID: 15172898
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Omalizumab beyond asthma.
    Sanchez J; Ramirez R; Diez S; Sus S; Echenique A; Olivares M; Cardona R
    Allergol Immunopathol (Madr); 2012; 40(5):306-15. PubMed ID: 22264640
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
    Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
    Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Omalizumab therapy in severe asthma: experience from the Spanish registry--some new approaches.
    Vennera Mdel C; Pérez De Llano L; Bardagí S; Ausin P; Sanjuas C; González H; Gullón JA; Martínez-Moragón E; Carretero JA; Vera E; Medina JF; Alvarez FJ; Entrenas LM; Padilla A; Irigaray R; Picado C;
    J Asthma; 2012 May; 49(4):416-22. PubMed ID: 22443408
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of topical nasal steroids in the treatment of children with otitis media with effusion and/or adenoid hypertrophy.
    Cengel S; Akyol MU
    Int J Pediatr Otorhinolaryngol; 2006 Apr; 70(4):639-45. PubMed ID: 16169093
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
    Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD;
    Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
    [TBL] [Abstract][Full Text] [Related]  

  • 49. RANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy.
    Zietkowski Z; Skiepko R; Tomasiak-Lozowska MM; Lenczewska D; Bodzenta-Lukaszyk A
    Int Arch Allergy Immunol; 2011; 154(1):25-32. PubMed ID: 20664274
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria.
    Song CH; Stern S; Giruparajah M; Berlin N; Sussman GL
    Ann Allergy Asthma Immunol; 2013 Feb; 110(2):113-7. PubMed ID: 23352531
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasmapheresis prior to omalizumab administration in a 15-year-old boy with severe asthma and very high IgE levels: sustained effect over 2 years.
    Kerzel S; Zemlin M; Rogosch T; Ollert M; Renz H; Klaus G; Maier RF
    Klin Padiatr; 2011 Nov; 223(6):356-9. PubMed ID: 22012605
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Omalizumab attenuates airway inflammation and interleukin-5 production by mononuclear cells in patients with severe allergic asthma.
    Takaku Y; Soma T; Nishihara F; Nakagome K; Kobayashi T; Hagiwara K; Kanazawa M; Nagata M
    Int Arch Allergy Immunol; 2013; 161 Suppl 2():107-17. PubMed ID: 23711861
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intractable otitis media with eosinophils: Importance of diagnosis and validity of treatment for hearing preservation.
    Nakagawa T; Matsubara A; Shiratsuchi H; Kakazu Y; Nakashima T; Koike K; Umezaki T; Komune S
    ORL J Otorhinolaryngol Relat Spec; 2006; 68(2):118-22. PubMed ID: 16446559
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Total antioxidant capacity, hydrogen peroxide, malondialdehyde and total nitric oxide concentrations in patients with severe persistent allergic asthma: its relation to omalizumab treatment.
    Yalcin AD; Gorczynski RM; Parlak GE; Kargi A; Bisgin A; Sahin E; Kose S; Gumuslu S
    Clin Lab; 2012; 58(1-2):89-96. PubMed ID: 22372350
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The anti-IgE antibody omalizumab as a probe to investigate the role of IgE in pathology.
    Mauro M; Incorvaia C; Formigoni C; Elia R; Russello M; Pellegrino D
    Panminerva Med; 2012 Dec; 54(4):305-12. PubMed ID: 23123583
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Basophil histamine release decreases during omalizumab therapy in allergic asthmatics.
    Noga O; Hanf G; Kunkel G; Kleine-Tebbe J
    Int Arch Allergy Immunol; 2008; 146(1):66-70. PubMed ID: 18087163
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
    Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
    J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma.
    Hoshino M; Ohtawa J
    Respiration; 2012; 83(6):520-8. PubMed ID: 22236804
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis.
    Chervinsky P; Casale T; Townley R; Tripathy I; Hedgecock S; Fowler-Taylor A; Shen H; Fox H
    Ann Allergy Asthma Immunol; 2003 Aug; 91(2):160-7. PubMed ID: 12952110
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.
    Dal Negro RW; Tognella S; Pradelli L
    J Asthma; 2012 Oct; 49(8):843-8. PubMed ID: 22954018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.